Literature DB >> 14967811

The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage.

Elizabeth Pohler1, Ashley L Craig, James Cotton, Laura Lawrie, John F Dillon, Pete Ross, Neil Kernohan, Ted R Hupp.   

Abstract

The esophageal epithelium is subject to damage from bile acid reflux that promotes normal tissue injury resulting in the development of Barrett's epithelium. There is a selection pressure for mutating p53 in this preneoplastic epithelium, thus identifying a physiologically relevant model for discovering novel regulators of the p53 pathway. Proteomic technologies were used to identify such p53 regulatory factors by identifying proteins that were overexpressed in Barrett's epithelium. A very abundant polypeptide selectively expressed in Barrett's epithelium was identified as anterior gradient-2. Immunochemical methods confirmed that anterior gradient-2 is universally up-regulated in Barrett's epithelium, relative to normal squamous tissue derived from the same patient. Transfection of the anterior gradient-2 gene into cells enhances colony formation, similar to mutant oncogenic p53 encoded by the HIS175 allele, suggesting that anterior gradient-2 can function as a survival factor. Deletion of the C-terminal 10 amino acids of anterior gradient-2 neutralizes the colony enhancing activity of the gene, suggesting a key role for this domain in enhancing cell survival. Constitutive overexpression of anterior gradient-2 does not alter cell-cycle parameters in unstressed cells, suggesting that this gene is not directly modifying the cell cycle. However, cells overexpressing anterior gradient-2 attenuate p53 phosphorylation at both Ser(15) and Ser(392) and silence p53 transactivation function in ultraviolet (UV)-damaged cells. Deletion of the C-terminal 10 amino acids of anterior gradient-2 permits phosphorylation at Ser(15) in UV-damaged cells, suggesting that the C-terminal motif promoting colony survival also contributes to suppression of the Ser(15) kinase pathway. These data identify anterior gradient-2 as a novel survival factor whose study may shed light on cellular pathways that attenuate the tumor suppressor p53.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14967811     DOI: 10.1074/mcp.M300089-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  47 in total

1.  Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance.

Authors:  Shawna Mae Hengel; Euan Murray; Simon Langdon; Larry Hayward; Jean O'Donoghue; Alexandre Panchaud; Ted Hupp; David R Goodlett
Journal:  J Proteome Res       Date:  2011-09-21       Impact factor: 4.466

2.  Mapping a noncovalent protein-peptide interface by top-down FTICR mass spectrometry using electron capture dissociation.

Authors:  David J Clarke; Euan Murray; Ted Hupp; C Logan Mackay; Pat R R Langridge-Smith
Journal:  J Am Soc Mass Spectrom       Date:  2011-05-11       Impact factor: 3.109

3.  A comparative study of gland cells implicated in the nerve dependence of salamander limb regeneration.

Authors:  Anoop Kumar; Graham Nevill; Jeremy P Brockes; Andrew Forge
Journal:  J Anat       Date:  2010-04-26       Impact factor: 2.610

4.  Development of a fluorescent monoclonal antibody-based assay to measure the allosteric effects of synthetic peptides on self-oligomerization of AGR2 protein.

Authors:  Terry A Gray; Euan Murray; Matthew W Nowicki; Lucy Remnant; Alexander Scherl; Petr Muller; Borek Vojtesek; Ted R Hupp
Journal:  Protein Sci       Date:  2013-07-25       Impact factor: 6.725

5.  The estrogen-responsive Agr2 gene regulates mammary epithelial proliferation and facilitates lobuloalveolar development.

Authors:  Suman Verma; Michael L Salmans; Mikhail Geyfman; Hong Wang; Zhengquan Yu; Zhongxian Lu; Fang Zhao; Steven M Lipkin; Bogi Andersen
Journal:  Dev Biol       Date:  2012-07-20       Impact factor: 3.582

6.  Surprisal analysis characterizes the free energy time course of cancer cells undergoing epithelial-to-mesenchymal transition.

Authors:  Sohila Zadran; Rameshkumar Arumugam; Harvey Herschman; Michael E Phelps; R D Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

7.  The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients.

Authors:  Dong L Barraclough; Angela Platt-Higgins; Suzete de Silva Rudland; Roger Barraclough; John Winstanley; Christopher R West; Philip S Rudland
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

8.  Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.

Authors:  Vijaya Ramachandran; Thiruvengadam Arumugam; Huamin Wang; Craig D Logsdon
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  The protein disulfide isomerase AGR2 is essential for production of intestinal mucus.

Authors:  Sung-Woo Park; Guohua Zhen; Catherine Verhaeghe; Yasuhiro Nakagami; Louis T Nguyenvu; Andrea J Barczak; Nigel Killeen; David J Erle
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-09       Impact factor: 11.205

10.  AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10-mediated regulatory pathway.

Authors:  Roman Hrstka; Pavla Bouchalova; Eva Michalova; Eva Matoulkova; Petr Muller; Philip J Coates; Borivoj Vojtesek
Journal:  Mol Oncol       Date:  2015-12-17       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.